• Poly(I:C) in Innate Immunity: Advanced Insights for Translat

  2026-06-12

  Discover how Poly(I:C), a synthetic double-stranded RNA analog, uniquely drives precise innate immune activation and dendritic cell maturation. This in-depth analysis reveals new mechanistic and assay design insights beyond standard protocols.

• Capsazepine as a Novel MCL1 Inhibitor to Reverse Tamoxifen R

  2026-06-12

  This study identifies capsazepine as a direct MCL1 inhibitor capable of overcoming tamoxifen resistance in estrogen receptor-positive breast cancer. Through virtual screening, molecular docking, and experimental validation, the research demonstrates capsazepine's ability to restore apoptotic sensitivity and suggests a promising strategy for endocrine-resistant breast cancer therapy.

• Phenacetin (SKU B1453): Reliable Solutions for PK and Cell A

  2026-06-11

  This article addresses real-world laboratory challenges in cell viability and pharmacokinetic studies, demonstrating how Phenacetin (SKU B1453) from APExBIO supports reproducible, data-driven research. Scenario-driven Q&As provide practical guidance on assay design, solubility optimization, and reliable sourcing, with evidence and protocol tips for biomedical researchers.

• EZ Cap™ Firefly Luciferase mRNA: Enhanced Assays & Imaging

  2026-06-11

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure sets a new benchmark in bioluminescent reporting by delivering more robust, sustained, and reproducible gene expression for both in vitro and in vivo workflows. Its engineered stability and translation efficiency empower sensitive mRNA delivery studies, high-fidelity gene regulation assays, and advanced bioluminescence imaging—enabling researchers to resolve common experimental bottlenecks and push molecular biology boundaries.

• Afatinib in Patient-Derived Assembloid Models: Mechanisms &

  2026-06-10

  Explore how Afatinib (BIBW 2992) empowers translational researchers to dissect EGFR, HER2, and HER4 signaling within next-generation assembloid cancer models. This article synthesizes mechanistic evidence, emerging preclinical data, and actionable protocol guidance, spotlighting how APExBIO’s high-purity Afatinib enables robust investigation of tumor-stroma interplay and drug resistance.

• IL-1β-Driven NF-κB Activation of ACE2 Enables Macrophage SAR

  2026-06-10

  Lee et al. demonstrate that IL-1β-induced NF-κB signaling upregulates ACE2 expression in macrophages, facilitating their susceptibility to SARS-CoV-2 infection. This mechanistic insight, enabled by a humanized ACE2 mouse model, suggests new avenues for understanding inflammatory modulation of viral entry in immune cells.

• LY2603618: A Precision Chk1 Inhibitor for Cancer Research

  2026-06-09

  LY2603618 stands out as a highly selective Chk1 inhibitor, enabling researchers to dissect DNA damage responses and optimize cancer chemotherapy sensitization. This guide translates the latest redox-focused findings and practical workflows into actionable protocols for non-small cell lung cancer and beyond.

• Demethyleneberberine Induces Senescence in NSCLC via c-Myc/H

  2026-06-09

  This study demonstrates that Demethyleneberberine (DMB), a natural isoquinoline alkaloid, induces cell cycle arrest and senescence in non-small cell lung cancer (NSCLC) cells by downregulating the c-Myc/HIF-1α pathway. These findings provide mechanistic insight into DMB’s anti-tumor activity and offer a rationale for its use as a research tool in NSCLC and related disease models.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Applied Ins

  2026-06-08

  The JC-1 Mitochondrial Membrane Potential Assay Kit empowers precise, ratiometric detection of mitochondrial health, enabling high-content apoptosis and function analysis across diverse research models. Its robust dual-fluorescence workflow, paired with reliable controls, accelerates translational breakthroughs in cancer and immunology. Discover optimized protocols, troubleshooting strategies, and real-world applications that set this APExBIO kit apart.

• Torin2 and the Future of mTOR Inhibition in Translational On

  2026-06-08

  This thought-leadership article explores the mechanistic depth and translational opportunities offered by Torin2, a next-generation mTOR inhibitor, in light of emerging insights into apoptotic signaling and RNA Pol II biology. We integrate recent findings, protocol best practices, and competitive positioning to provide actionable guidance for cancer researchers seeking to unravel the complexities of the PI3K/Akt/mTOR pathway.

• ATRA Overcomes PARP Inhibitor Resistance in Platinum-Treated

  2026-06-07

  This study demonstrates that all-trans retinoic acid (ATRA) can sensitize epithelial ovarian cancer (EOC) cells to PARP inhibition following cisplatin-induced resistance. The findings provide a mechanistic basis for combining ATRA with PARP inhibitors such as Niraparib to improve outcomes in platinum-resistant EOC models.

• Artesunate: Mechanisms and Benchmarks for Cancer Research

  2026-06-06

  Artesunate is a high-purity artemisinin derivative with robust anti-cancer properties, including potent inhibition of small cell lung carcinoma in vitro. Its mechanisms involve both ferroptosis induction and caspase-11-mediated pyroptosis inhibition, supporting its use as a precision tool in oncology research.

• PD 0332991 (Palbociclib) HCl: Precision in Rb-Driven Tumor S

  2026-06-05

  Explore the advanced biology and translational promise of PD 0332991 (Palbociclib) HCl, a selective CDK4/6 inhibitor, with a focus on Rb pathway vulnerabilities and protocol optimization. This article offers unique insights for oncology research and assay design.

• Machine Learning for Predicting LNPs in mRNA Vaccine Design

  2026-06-05

  This study pioneers the use of machine learning to predict the efficacy of lipid nanoparticle (LNP) formulations for mRNA vaccines, highlighting the critical role of ionizable lipids like Dlin-MC3-DMA. The integration of computational modeling and experimental validation accelerates LNP optimization, offering a robust framework for advancing RNA delivery technologies.

• Norovirus Utilizes NINJ1 for Selective Viral Protein Secreti

  2026-06-04

  This study reveals how murine norovirus (MNoV) hijacks the host cell death effector NINJ1 to orchestrate the selective secretion of its NS1 protein, leveraging caspase-3–mediated cleavage and NINJ1 oligomerization. These findings provide a mechanistic bridge between programmed cell death, unconventional secretion pathways, and viral immune evasion strategies.

14598 records 1/974 page Next 12345 下5页 Last page